arrow
T

Tarah J. Ballinger

Department of Hematology and Oncology
H指数:19
被引数:2,001

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A multi-dimensional framework for predicting taxane-induced peripheral neuropathy in Black women with breast cancer: findings from ECOG-ACRIN EAZ171

一种用于预测黑种乳腺癌女性紫杉烷诱导性周围神经病变的多维框架:ECOG-ACRIN EAZ171研究的结果

2026-08-260
OAAI
Impact of patient-reported taxane-induced peripheral neuropathy on dose reductions or worsening quality of life in Black women with breast cancer: Analysis from ECOG-ACRIN EAZ171

黑种人乳腺癌患者报告的紫杉烷类诱导周围神经病变对剂量减少或生活质量恶化的影响:ECOG-ACRIN EAZ171研究分析

Cancer
IF5.1
2026-05-290
OAAI
A phase 1 study of ASTX727 plus talazoparib in patients with triple-negative or hormone resistant/HER2-negative metastatic breast cancer

ASTX727联合talazoparib治疗三阴性或激素抵抗/HER2阴性转移性乳腺癌的Ⅰ期研究

Cancer
IF5.1
2026-04-140
OAAI
Racial differences in breast cancer-specific mortality and CVD-specific mortality after breast cancer in post-menopausal women

绝经后女性乳腺癌患者中,不同种族在乳腺癌特异性死亡率和心血管疾病特异性死亡率方面的差异

2025-12-170
OAAI
A Randomized Phase 2 Study of Neratinib With or Without Fulvestrant for Patients With HER2-Positive, Estrogen Receptor-Positive Metastatic Breast Cancer

一项关于奈拉替尼联合或不联合氟维司群治疗HER2阳性、雌激素受体阳性转移性乳腺癌的随机II期研究

2025-05-160
PRE
Survivorship, Version 2.2024 Featured Updates to the NCCN Guidelines

生存率,版本2.2024版NCCN指南特色更新

2024-12-011
OA
Use of web-based decision support to improve informed choice for chemoprevention: a qualitative analysis of pre-implementation interviews (SWOG S1904)
2024-09-270
OAAI
NKG2A Is a Therapeutic Vulnerability in Immunotherapy Resistant MHC-I Heterogeneous Triple-Negative Breast Cancer
2023-10-036
OAAI
SWOG 1904: Cluster-randomized controlled trial of patient and provider decision support to increase chemoprevention informed choice among women with atypical hyperplasia or lobular carcinoma in situ (MiCHOICE)
2023-03-010
PRE
Survivorship, Version 1.2022 Featured Updates to the NCCN Guidelines

Survivorship,1.2022版更新了NCCN指南

2022-10-0118
OA